NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Aktis Oncology, Inc. (AKTS) Stock Analysis

Aktis Oncology, Inc. (AKTS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

AKTS

$27.05

+$0.40 (+1.50%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AKTS with… →

AKTS Key Statistics

As of Sep 4, 2026
Trading
Open
$26.18
Previous Close
$26.65
Day's Range
26.18–27.20
52-Week Range
14.72–34.19
Volume
159.20K
Valuation
Market Cap
$1.50B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
149.55
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.34
Financials (FY)
Revenue (FY)
$6.50M+336.92%
Net Income (FY)
−$63.73M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
53.75M
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
392.17K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AKTS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$6.50M−$63.73M−980.9%
2024$1.49M−$43.98M−2957.6%
2023$0.00−$28.64M—
2022$0.00−$17.93M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$6.50M—−$74.68M−$63.73M−980.9%
2024$1.49M—−$52.05M−$43.98M−2957.6%
2023$0.00—−$34.79M−$28.64M—
2022$0.00—−$19.76M−$17.93M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AKTS Valuation vs Biotechnology Median

Median of 656 stocks
MetricAKTSBiotechnology medianvs median
P/S ratio149.5515.269.8x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Aktis Oncology, Inc. (AKTS) is capitalised at $1.50B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 79 employees.

The most recent close on file for AKTS is $27.05, dated September 4, 2026. That is +$0.40 (+1.50%) against the previous close. The 52-week range on file runs from $14.72 to $34.19. The latest close sits 83.76% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $6.50M. Against the prior fiscal year total of $1.49M, that is a change of +336.92%. The same year closed with a net loss of $63.73M. Profit margin runs at 0%. Trailing earnings per share are −1.34.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $6.50M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 149.55. On price-to-sales that is 9.8 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The stored price history starts on January 9, 2026, and the total return since then is +20.76%.

Growth & Income

The record shows no dividend for AKTS.

2026 is still running; the price is +20.76% year to date.

Peer Comparison

Aktis Oncology, Inc. (AKTS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Aktis Oncology, Inc. AKTS $1.50B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Aktis Oncology, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Aktis Oncology, Inc.

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.

Visit website →